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Abstract
This study was undertaken in order to provide further insight into the role of leucine supplementation in the skeletal muscle
regeneration process, focusing on myofiber size and strength recovery. Young (2-month-old) rats were subjected or not to
leucine supplementation (1.35 g/kg per day) started 3 days prior to cryolesion. Then, soleus muscles were cryolesioned and
continued receiving leucine supplementation until 1, 3 and 10 days later. Soleus muscles from leucine-supplemented
animals displayed an increase in myofiber size and a reduction in collagen type III expression on post-cryolesion day 10.
Leucine was also effective in reducing FOXO3a activation and ubiquitinated protein accumulation in muscles at post-
cryolesion days 3 and 10. In addition, leucine supplementation minimized the cryolesion-induced decrease in tetanic
strength and increase in fatigue in regenerating muscles at post-cryolesion day 10. These beneficial effects of leucine were
not accompanied by activation of any elements of the phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin
signalling pathway in the regenerating muscles. Our results show that leucine improves myofiber size gain and strength
recovery in regenerating soleus muscles through attenuation of protein ubiquitination. In addition, leucine might have
therapeutic effects for muscle recovery following injury and in some muscle diseases.
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Introduction
Mammalian skeletal muscle has the ability to adapt to
environmental conditions, including a remarkable capacity to
regenerate after damage. This regeneration process is highly
synchronised and complex, involving the activation of various
cellular responses, initially characterised by myofiber necrosis and
activation of inflammatory cells [1]. This step is followed by
activation of satellite cells, which undergo proliferation, differen-
tiation and fusion to one another or to uninjured portions of the
myofiber in order to repair the muscle tissue and restore its
function [2,3,4].
Recovery of the myofiber cross-sectional area (CSA) is a crucial
event in the process of muscle regeneration. Accordingly, studies
have shown that the recovery of skeletal muscle after damage is
highly regulated by intracellular signalling pathways that control
protein turnover, maintaining a balance between the synthesis and
degradation of proteins. The activation of elements involved in the
mRNA translation process, such as the kinase mechanistic target
of rapamycin (mTOR) and its downstream targets, is an essential
step for the muscle regenerative response [5,6].
The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is
the major signalling pathway that regulates translation of mRNA
in skeletal muscle upon upstream inputs such as growth factors and
amino acid availability. The mTOR kinase and its downstream
substrates—the 70-kDa ribosomal protein S6 kinase (p70S6K);
eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1);
and the eIF4F complex, which is composed of eIF4E, eIF4G, and
eIF4A—are the crucial elements in the regulation of mRNA
translation [7,8,9,10]. During the translation, the small 40S
ribosome subunit is recruited to the m7G cap structure of the 59
end of the mRNA, where it scans for the start codon and is
assembled into the complete ribosome. Access to the cap structure
is provided by eIF4E, which is a major determinant of mRNA
efficiency. Hyperphosphorylation of 4E-BP1 releases it from eIF4E
and facilitates this binding. In addition, phosphorylation of
mTOR activates p70S6K, which in turn promotes the activation
of secondary structures in the 59 untranslated region of mRNA to
facilitate ribosome scanning [8,11,12]. Furthermore, studies have
shown that amino acids are able to induce an increase in
intracellular Ca2+ [Ca2+]i; which triggers mTOR and vacuolar
protein sorting 34 (Vps34) activation; more specifically the rise in
[Ca2+]i increases the direct binding of Ca2+/calmodulin to a
conserved motif in Vps34 that is required for lipid kinase activity
and increased mTOR signaling [13,14].
Molecular mechanisms that modulate protein degradation, such
as the ubiquitin-proteasome system (UPS) pathway, the principal
agent of proteolytic activity in muscle, also modulate skeletal
muscle adaptation over the course of muscle regeneration
[15,16,17]. During degradation of damaged muscle tissue,
ubiquitin conjugates are bound to target proteins via a ubiquitin
protein ligase, E3, which presents substrate recognition sites to the
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ubiquitin molecule [16]. This ubiquitination process is dependent
on a forkhead box-O (FOXO) family of transcription factor, such
as FOXO3a, which are responsible for transcription activation of
E3 ligases [18,19]. Finally, the termini of ubiquitinated proteins
are tagged for degradation in the proteasome [20,21,22].
Although skeletal muscle regeneration has been explored
carefully at the structural and cellular levels for many years, the
identification of strategies to improve this process is on-going. In
addition to pharmacological therapies and treatments that have
ergogenic effects, certain essential amino acids (especially leucine)
have been shown to modulate protein turnover in skeletal muscle,
favouring mass gain [23,24]. Leucine alone is able to induce
phosphorylation of mTOR in skeletal muscle, modulating the
translation process in a way similar to that achieved by a full
complement of essential amino acids. In vivo studies have shown
that the effects that leucine supplementation has on muscle tissue
are associated with the phosphorylation of p70S6K and 4E-BP1, as
well as with release of the eIF4F complex [25,26,27]. However, the
process of muscle protein degradation can be inhibited by leucine
supplementation. In fact, it has demonstrated that leucine
supplementation, by minimising the expression of E3 ligases
[28], attenuates the muscle wasting induced by immobilization. In
addition, leucine has no apparent effect on the recovery of protein
synthesis after muscle atrophy.
Leucine has anti-catabolic effects, as well as anabolic effects,
which increase translational efficiency. Therefore, its use as a
therapeutic agent could promote the recovery of skeletal muscle
mass after damage. In fact, leucine has been shown to improve the
overall morphology of regenerating muscles [29], although the
intracellular mechanisms involved have not been fully explored.
Therefore, the aim of this study was to gain further insight into the
effects that leucine supplementation, started 3 days prior to muscle
injury, has on the morphological, molecular, and functional
recovery of damaged skeletal muscle in rats. Our results show that
leucine improves myofiber size gain and strength recovery in
regenerating soleus muscles through attenuation of protein
ubiquitination.
Materials and Methods
This study was carried out in strict accordance with the ethical
principles for animal research set forth by the Brazilian College of
Animal Experimentation. The protocol was approved by the
Ethics in Animal Research Committee of the Institute of
Biomedical Sciences at the University of Sao Paulo (Permit
Number: 87/2011). Surgical procedures were performed under
ketamine and xylazine, or sodium thiopental or tribromoethanol
anesthesia, and all efforts were made to minimize suffering. At the
end of protocols, all animals were deeply anesthetized and
euthanized by cervical dislocation.
Animals
In this study, we used 2-month-old male Wistar rats (n=48),
weighing 283.3610.8 g. Animals were housed in standard plastic
cages in a temperature- and light-controlled environment (24uC;
12/12-h light/dark cycle), with ad libitum access to standard rat
chow and water.
Experimental design
Animals received leucine supplementation or not and were
submitted to cryolesion of the soleus muscle of the left hind limb.
The contralateral soleus muscle (right hind limb) was used as an
intact control [6,30]. In order to investigate the effects of leucine
supplementation on muscle regeneration, muscles were randomly
divided into four groups: control (untreated, right hind limb;
n=6); leucine supplementation only (Leu, right hind limb; n=6);
cryolesion only (Cryo, untreated, left hind limb; n = 6) and leucine
supplementation combined with cryolesion (Cryo+Leu, treated,
left hind limb; n=6).
Distinct muscles (n = 6; each group) were used in the
experiments to measure muscle function. Beginning at 3 days
prior to cryolesion and continuing until the end of each
experimental period (until post-cryolesion days 1, 3, and 10),
leucine (L-Leucine; Ajinomoto, Japan) was administered once a
day by oral gavage at a dose of 1.35 g/kg body weight [27,31,32].
Leucine was dissolved in distilled water and each animal was
gavaged with a 5 mL volume of distilled water [27]. In our
previous experiments, muscles from saline-gavaged rats did not
show morphological changes compared to those from intact
animals (data not shown). Prior to cryolesion, the animals were
anaesthetized with ketamine and xylazine (95 and 12 mg/kg BW,
i.p.), and all efforts were made to minimize suffering.
In each animal, one soleus muscle (left hind limb) was surgically
exposed by a lateral incision between the fascias of the anterior
and posterior muscle groups until the dorsal surface of the muscle
was completely exposed. The cryolesion consisted of one freeze-
thaw cycle of the muscle in situ. An iron bar (0.460.4 cm) was
precooled in liquid nitrogen. The flat side of the bar was brought
into full contact with the soleus muscle for 10 s. After the muscle
had thawed, the wounds were closed with 6-0 silk sutures. For
several min thereafter, the animals were held on a warming plate
(37uC) to avoid hypothermia.
On post-cryolesion days 1, 3, and 10, the animals received the
last dose of leucine. One hour later [27] each rat was again deeply
anesthetized with sodium thiopental (5 mg/100 g BW, i.p.) and
the soleus muscles (left and right hind limb) were removed and
weighed. Subsequently, animals were euthanized.
Morphometric and quantitative analyses
After being removed from the animals, the muscles were frozen
in melting isopentane and stored in liquid nitrogen. Frozen
muscles were cut into 10-mm cross sections on a cryostat (CM3050;
Leica, Germany). To reveal the overall morphology, unfixed
histological sections were stained with a solution of aqueous
toluidine blue and borax (1% w/v for both). The stained sections
were analysed under a light microscope (PCM 2000; Nikon, USA).
The morphometric and quantitative analyses were conducted with
a digitizing unit linked to computer software (Image-Pro Plus;
Media Cybernetics, USA). To assess the myofiber cross-sectional
area (CSA; mm2), a total of approximately 500 myofibers per
muscle were measured. In the cryolesion groups, the CSA
measurements were obtained only from the regenerating myofiber
with centralized nuclei [6]. CSA measurements were expressed as
mean 6 SD. Myofibers with centralized nuclei were counted in
three entire cross sections for each group, and the total area of the
section was measured using the software ImagePro Plus. Regen-
erating myofibers with centralized nuclei were expressed as
number per square millimeter (mm2). Figures were mounted
using Adobe PhotoShop v7.0, with image manipulation being
restricted to overall threshold and brightness adjustments.
Immunostaining
Muscle cross sections to be used for immunodetection of
macrophage, collagen type III, and FOXO3a were fixed with 4%
paraformaldehyde in 0.2 M phosphate buffer (PB) for 10 min at
room temperature, blocked with 0.1 glycine in phosphate-buffered
saline (PBS) for 5 min, and permeabilized in 0.2% Triton X-100/
PBS for 10 min. The slides were incubated overnight in a moisture
Effect of Leucine in Skeletal Muscle Regeneration
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chamber at 4uC with a solution containing the primary antibodies
together with 3% normal goat serum and 0.3% Triton X-100/
0.1 M PB. After the slides had been washed (three 10-min washes
with 0.1 M PB), a solution containing the respective secondary
antibodies and 0.3% Triton X-100/0.1 M PB was added, and the
slides were maintained in this solution for 2 h in a dark room. The
slides were again washed in 0.1 M PB (three 10-min washes), after
which they were mounted with Vectashield mounting medium
containing 49,6-diamidino-2-phenylindole (Vector Laboratories)
and coverslipped.
The primary antibodies used were: mouse monoclonal anti-
macrophage MAC387 (1:200; Abcam Inc, Cambridge, MA,
USA); mouse monoclonal anti-Collagen III (1:250; Abcam Inc,
Cambridge, MA, USA); and, rabbit polyclonal anti-FOXO3a
(1:300; Abcam Inc, Cambridge, MA, USA). The following
secondary antibodies were: FITC-conjugated goat anti-mouse
(1:200; Jackson ImmunoResearch, West Grove, PA, USA); CY3
donkey anti-mouse (1:200; Jackson ImmunoResearch, West
Grove, PA, USA); and, CY2 goat anti-rabbit (1:200; Jackson
ImmunoResearch, West Grove, PA, USA).
Macrophages and the nuclei positive for FOXO3a (activated
FOXO3a) were counted in three entire cross sections for each
group, and the total area of the section was measured using the
software ImagePro Plus. The volume of muscle samples was
calculated as the product of the CSA of the section and the section
thickness (10 mm). The quantity of macrophages and FOXO3a
positive nuclei was expressed as number per cubic millimeter [33].
A planimetry system was used for the analysis of the
intramuscular collagen type III density by scoring the points
containing 500 line intersections per field. The coincident points in
the endomysium and perimysium in three areas per section in four
sections per animal corresponded to a total of 6,000 points per
animal. The relative area of collagen III in muscle tissue (area
density) was calculated by dividing the sum of the number of the
coincident points in the straight line intersections in the connective
tissue by the total number of points and was expressed as a
percentage of whole muscle cross sections [34].
The stained sections were analysed in a Nikon microscope
(PCM2000, Nikon, Melville, New York, USA). Figures were
mounted using Adobe PhotoShop v7.0, with image manipulation
being restricted to overall threshold and brightness adjustments.
Western blot analysis
To quantify the expression of elements of the PI3K/Akt/
mTOR pathway, soleus muscles were homogenised in an
extraction solubilisation buffer, composed of 90 mM KCl,
10 mM 4-2-hydroxyethyl-1-piperazineethanesulfonic acid, 3 mM
MgCl2+, 5 mM ethylenediaminetetraacetic acid (EDTA), 1%
glycerol, 1 mM dithiothreitol, 0.04% sodium dodecyl sulfate,
proteinase, and phosphatase inhibitor cocktail (1:100; Sigma-
Aldrich, USA). For studies to detect the amount of ubiquitinated
proteins, soleus muscles were homogenized in an extraction
solubilisation buffer, composed of 0.625% non-ionic detergent
(Nonidet P-40; Sigma-Aldrich, USA), 0.625% sodium deoxycho-
late, 6.25 mM sodium phosphate, 1 mM EDTA (pH 7.4)
containing 10 mg/ml of protease inhibitor cocktail (Sigma-Aldrich,
USA). Homogenates were centrifuged at 12,0006g for 10 min at
4uC, the supernatant was collected, and protein was quantified by
Bradford assay (Bio-Rad, USA) with bovine serum albumin as a
standard [35]. Equal amounts of protein (50 mg) were separated on
6–15% sodium dodecyl sulfate-polyacrylamide gels, electropho-
resed, and transferred to a nitrocellulose membrane (Bio-Rad,
USA). The membranes were stained with Ponceau S to determine
the protein content and then rinsed with Tris-buffered saline/
Tween solution (0.5 M NaCl; 50 mM Tris-HCl, pH 7.4; and
0.1% Tween 20). Membranes were incubated overnight at 4uC
with primary antibodies. After a 30 min wash in Tris-buffered
saline/Tween solution, membranes were incubated with second-
ary antibodies for 1 h at room temperature. The membranes were
again washed for 30 min in Tris-buffered saline/Tween solution.
Detection of the labelled proteins was achieved using the enhanced
chemiluminescence system (ECL; Amersham, UK) and autoradi-
ography. Densitometry analysis was performed by using ImageJ
software (Scion Corp., National Institutes of Health, Bethesda,
Maryland, USA). Experiments were performed on four separate
samples from each group.
The primary antibodies used for Western blotting were rabbit
polyclonal antibodies raised against mTOR, phospho-mTOR at
Ser2448 residue, phospho-p70S6K at Ser371 and Thr389 residue, 4E-
BP1, phospho-4E-BP1 at Thr70 and Thr37/46 residues, and eIF4E
(1:1,000; Cell Signaling Technology, USA). Targeted bands
were normalised to glyceraldehyde-3-phosphate dehydrogenase
(1:1,000; Cell Signaling Technology, USA). In addition, we used a
rabbit polyclonal antibody raised against ubiquitin (1:1,500;
Boston Biochem, USA). The secondary antibody used for all
Western blots was peroxidase-conjugated goat anti-rabbit IgG
(AffiniPure, 1:10,000; Jackson ImmunoResearch Laboratories
Inc., USA).
In vivo muscle function experiments
On post-cryolesion day 10, animals were anaesthetized with
tribromoethanol (20 mg/100 g body weight, i.p.). The sciatic
nerve was then exposed through a lateral incision on the thigh,
and an electrode was connected. The innervations of the sciatic
nerve to the soleus muscle were carefully isolated from those
originating from other nerves. The distal lateral and medial
tendons of the gastrocnemius muscle were surgically separated
from the soleus tendon to avoid injuries to the innervations of
soleus muscles in the mid-belly region between the soleus and
gastrocnemius muscles. The rats were then placed on an acrylic
platform with a metallic bar crossing the knee in order to
immobilize the limb. The soleus tendon was connected to a force
transducer coupled to a computer that was used in order to collect
and analyse data related to the strength generated by the muscle
contraction. Muscle twitch strength and tetanic force were
recorded using a data acquisition system (Biopac Systems, USA).
Muscle strength was analysed using the AcqKnowledge program,
version 3.9.1.6 (Biopac Systems, USA). Rats were submitted to
external warming in order to maintain core temperature
throughout the procedure.
At the start of the experiment, the muscle was set to the
optimum length (L0, defined as the length resulting in maximum
twitch strength). There was a 2-min rest period between stimuli
[36]. To achieve the maximal plateau strength with the minimal
frequency, we chose to use stimuli of 350 Hz for measuring the
maximum isometric tetanic strength and 200 Hz for measuring
fatigue [37].
Based on Chan & Head [37], isolated twitches (0.2 Hz) were
generated over a 2-min period, followed by a pre-fatigue
maximum tetanic contraction (induced at 350 Hz for 2 s) in
each soleus muscle. We then performed a fatigue protocol,
which consisted of ten 2-s stimulations (at 200 Hz tetanus), each
followed by a 4-s rest. At the end of the fatigue protocol, a 2-min
rest-period was given to the muscle by stimulating it at 0.2 Hz,
followed by a post-fatigue maximum tetanic contraction (induced
at 350 Hz for 2 s). We observed no differences among the groups
in terms of twitch parameters, such as the time-to-peak and half-
relaxation time (data not shown). Tetanic strength is expressed in
Effect of Leucine in Skeletal Muscle Regeneration
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millinewtons. Development of muscle fatigue was measured at four
time points (1st, 4th, 7th, and 10th contractions).
Statistical analysis
Data are presented as mean and standard deviation. We used
mixed models for repeated measures in order to evaluate the
effects that cryolesion and leucine supplementation have on
maximum tetanic strength and the development of muscle fatigue.
Analysis of variance (the general linear model) was used in order to
evaluate the effects that cryolesion and leucine supplementation
have on body weight, muscle weight, CSA, area density of
collagen, protein expression analysis, and quantification of
inflammatory cells, and FOXO3a positive nuclei. Student t-test
was used in order to evaluate the effects that leucine supplemen-
tation has on incidence of myofibers with centralized nuclei.
Whenever a significant F-value was obtained, Tukey’s post-hoc test
was performed for multiple comparison purposes (SAS 9.2
software; SAS Institute Inc., USA). Values of p,0.05 were
considered statistically significant.
Results
Body weight, muscle weight, and muscle histology
Body weight remained unchanged in all of the animals
evaluated. The food consumption was also unaltered in all groups
(data not shown). In the control groups, soleus muscle weight was
unaltered over the course of 3 and 10 days of observations
(Table 1). However, there was a rise in soleus muscle weight from
Leu group at day 10 when compared to that from day 1 (33%, p,
0.05, Table 1). Damaged soleus muscles in the Cryo and Cryo+
Leu groups showed a significant increase in their weights when
compared to those from Control group on post-cryolesion day 1
(30% increase in both groups, p,0.05, Table 1). On post-
cryolesion day 3, soleus muscle weights from Cryo and Cryo+Leu
groups were decreased when compared to those from day 1 (31%
in both, Table 1). On post-cryolesion day 10, soleus muscle weight
was reduced in the Cryo group (31%), but not in Cryo+Leu group
when compared to that from Cryo and Cryo+Leu groups,
respectively, on day 1 (Table 1).
Histological cross sections of soleus muscles were stained with
toluidine blue and microscopically analysed on the days
corresponding to post-cryolesion days 1, 3, and 10 (Figure 1A).
The intact control muscle exhibited polygonal myofibers with
peripheral nuclei, i.e., a normal tissue structure (Figure 1A-a). On
leucine supplementation day 10, the myofiber CSA was 45%
larger in a soleus muscle from a Leu group than in one obtained
from a control group rat (p,0.05, Figure 1A-b, and B).
On post-cryolesion day 1, the muscles from the Cryo and Cryo+
Leu groups showed significant signs of damage, as evidenced by
the presence of hyper-contracted myofibers, empty spaces between
myofibers, and inflammatory cells; which indicated myonecrosis,
tissue disruption, and oedema (Figure 1A-c, and A-d ). These
markers of damage reflected on increased muscle weight in both
Cryo and Cryo+Leu groups (30% in both, Table 1), as previously
mentioned. On post-cryolesion day 3, the muscles from the Cryo
and Cryo+Leu groups still presented extensive damage, indicated
by clear areas among the myofiber and extensive inflammatory
cell infiltration (Figure 1A-e, and A-f ). However the oedema
significantly reduced, as shown by unaltered muscle weights in
both Cryo and Cryo+Leu groups when compared to those from
control group (Table 1).
Soleus muscles evaluated on post-cryolesion day 10 exhibited an
apparent reduction in the inflammatory process when compared
with those evaluated on post-cryolesion days 1 and 3. In addition,
the Cryo and Cryo+Leu group soleus muscles showed regenerat-
ing myofibers with centralised nuclei, a feature not observed in the
corresponding control muscles (Figure 1A-g and A-h). Cryo soleus
muscles showed a significantly (53%) smaller CSA when compared
with the corresponding intact control muscles (p,0.05, Figure 1A-
g and B). At the same time point, the Cryo+Leu group soleus
muscles showed inflammatory infiltration affecting a smaller area
(Figure 1A-h) and the myofibers of those muscles were 40% larger,
when compared with Cryo group muscles (p,0.05, Figure 1B). In
addition, soleus muscle from Cryo and Cryo+Leu groups analysed
on post-cryolesion day 10 showed a similar number of regener-
ating myofibers with centralized nuclei (Figure 1C).
Area density of collagen type III and incidence of
macrophages are reduced in regenerating muscles
supplemented with leucine
Histological cross sections of soleus muscles collected on post-
cryolesion day 10, were immunostained against collagen type III
and analysed. Cryo group showed an increased area density of
collagen type III when compared to that from C and Leu groups
(180% of increase, p,0.05, Figure 2A and B). There was a decrease
of area density of collagen type III in Cryo+Leu group when
compared to that fromCryo group (60%, p,0.05, Figure 2A and B).
In addition, the number of macrophages in soleus muscles from
Cryo+Leu group evaluated on post-cryolesion day 3 was decreased
when compared to that from Cryo group (60%, p,0.05, Figure 3).
Table 1. Soleus muscle weight and body weight of rats at post-cryolesion days 1, 3, and 10.
Post-cryolesion time point Muscle weight (g) Body weight (g)
Mean±SD Mean±SD
Group Group
Control Leu Cryo Cryo+Leu Control/Cryo Leu/Cryo+Leu
Day 1 0.1060.01 0.0960.03 0.1360.02a 0.1360.02a 293.2617.8 276.868.7
Day 3 0.1060.01 0.0960.06 0.0960.02b 0.0960.01b 282.1623.8 266.4611.7
Day 10 0.1160.03 0.1260.06b 0.0960.01b 0.1160.02 292.366.0 291.963.7
Control: intact muscles; Leu: muscles supplemented with leucine; Cryo: cryolesioned muscles; Cryo+Leu: cryolesioned muscles supplemented with leucine;
Control/Cryo: animals that had the left soleus muscle cryolesioned and the right soleus muscles used as control; Leu/Cryo+Leu: animals that were supplemented with
leucine and had the left soleus muscle cryolesioned and the right soleus muscles used as control. ap,0.05 vs. Control and Leu in the same post-cryolesion time point;
bp,0.05 vs. matched group on Day 1 after cryolesion (analysis of variance followed by Tukey’s post hoc test for multiple comparison.
doi:10.1371/journal.pone.0085283.t001
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Expression of elements within the PI3K/Akt/mTOR
signalling pathway
Since we found no effect of leucine in the expression of elements
within the PI3K/Akt/mTOR pathway, i.e. phosphorylated
p70S6K at Ser371 and Thr389 residues, in regenerating muscles
from 3 days post-cryolesion (data not shown), and muscles from 1
and 3 days post-cryolesion had similar morphological features of
early damage; we decided to focus our western blot analyses for
elements within the PI3K/Akt/mTOR pathway in muscles from
10 days post-cryolesion.
We found it surprising that the leucine supplemented-only
group had a slight decrease on mTOR phosphorylation at
Ser2448 residue (26%, p,0.05, Figure 4A and B) and no
changes in the expression of other PI3K/Akt/mTOR pathway
elements analysed, including mTOR, p-p70S6K at Ser371 and
Thr389 residues; 4E-BP1; p-4E-BP1 at Thr70 and Thr37/46
residues; and eIF4E (Figure 4A and B). On post-cryolesion
day 10, muscles from Cryo group showed an increase in the
expression of mTOR, p-mTOR (at Ser2448), and p-p70 (at Ser371
and Thr389) when compared with that observed for the
intact control muscle (90%, 30%, 100% and 80%; respectively,
p,0.05, Figure 4A and B). In addition, the expression of mTOR
and p-mTOR (at Ser2448) was significantly decreased in the Cryo+
Leu group muscles (42% and 45%, p,0.05, Figure 4A and B);
and the cryolesion-induced increase in p-p70 (at Ser371 and
Thr389) was unaffected in the Cryo+Leu group muscles (Figure 4A
and B).
Attenuation of ubiquitinated protein accumulation and
of FOXO3a activation on regenerating muscles
supplemented with leucine
Activation of FOXO3a transcription factor was assessed by
quantifying the number of nuclei positive for FOXO3a in skeletal
muscle tissues collected on post-cryolesion days 3 and 10. On post-
Figure 1. Effects of leucine supplementation on skeletal muscle morphology. A: Histological features of soleus muscle cross sections. a: C,
intact control muscle; b: Leu, control muscle supplemented only with leucine from the time point of post-cryolesion day 10; c: Cryo, damaged muscle
analysed on post-cryolesion day 1; d: Cryo+Leu, leucine- supplemented damaged muscle analysed on post-cryolesion day 1; e: Cryo, damaged muscle
analysed on post-cryolesion day 3; f: Cryo+Leu, leucine-supplemented damaged muscle analysed on post-cryolesion day 3; g: Cryo, damaged muscle
analysed on post-cryolesion day 10; and h: Cryo+Leu, leucine-supplemented damaged muscle analysed on post-cryolesion day 10. Note that the
intact control muscle (a) and the leucine supplemented-only muscle (b) have normal morphology. At post-cryolesion day 1, note the hyper-
contracted fibers, i.e., fibers with dark regions (arrows in c and d of panel A), which result from myofiber disruption. In addition, there are clear spaces
between the cells, indicating regions of totally destroyed myofibers and presence of inflammatory cells (asterisks). At post-cryolesion day 3, note the
intense inflammatory process in Cryo and Cryo+Leu group muscles (asterisks in e and f of panel A). At post-cryolesion day 10, Cryo and Cryo+Leu
group muscles have regenerating myofibers with centralized nuclei (arrowheads in g and h of panel A) and apparently less inflammatory infiltration in
the Cryo+Leu group (asterisks in g and h). Toluidine blue staining. Bar = 50 mm. B: Myofiber cross-sectional area (CSA; mm2) of soleus muscles. C: intact
control muscles; Leu: control muscles supplemented only with leucine from the time point of post-cryolesion day 10; Cryo: damaged muscles
analysed on post-cryolesion day 10; and, Cryo+Leu: leucine-supplemented damaged muscles analysed on post-cryolesion day 10. Data are presented
as mean6SD (n = 6). a p,0.05 vs. C and Leu; b p,0.05 vs. Cryo. C: Incidence of myofibers with centralized nuclei per area (mm2) of soleus muscle
tissue. Cryo: damaged muscles analysed on post-cryolesion day 10; Cryo+Leu: leucine-supplemented damaged muscles analysed on post-cryolesion
day 10. Data are presented as mean6SD (n = 6).
doi:10.1371/journal.pone.0085283.g001
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cryolesion day 3, muscles from Cryo group showed a robust
increase in the number of nuclei positive for FOXO3a, when
compared to those from control group (13 folds, p,0.05, Figure 5A
and B). Muscles from Cryo+Leu group had a decreased activation
of FOXO3a when compared to those from Cryo group (58%, p,
0.05, Figure 5A and B).
On post-cryolesion day 10, muscles from Cryo group still
showed a great increase in activation of FOXO3a, when
compared to those from control group (5.6 folds, p,0.05,
Figure 5A and B). Similarly to the results from 3 days post-
cryolesion, there was a reduced activation of FOXO3a in muscles
from Cryo+Leu group when compared to those from Cryo group
(55%, p,0.05, Figure 5A and B).
The amount of ubiquitin-conjugated proteins in the soleus
muscle was notably elevated in the Cryo group than in the control
group on post-cryolesion days 3 and 10 (70% and 65%;
respectively, p,0.05, Figure 6A and B). There was no difference
between the muscles from the Leu group and the intact control
muscles. However, at the same time points (post-cryolesion days 3
and 10), the cryolesion-induced increase in the amount of
ubiquitinated protein was attenuated in the Cryo+Leu group
muscles (30% and 25%; respectively, p,0.05, Figure 6A and B).
Leucine supplementation prevents loss of function in
regenerating muscles
The influence of leucine supplementation on the functional
recovery of regenerating soleus muscles was evaluated through the
analysis of the maximum tetanic strength and the development of
muscle fatigue on post-cryolesion day 10. There was no difference
between the control and Leu groups in terms of the results of pre
and post-fatigue tetanic strength stimulations. However, compar-
ing Cryo group muscles and control group muscles, strength
production at pre-fatigue tetanic stimulus was 50% lower in the
former (p,0.05, Figure 7A). In addition, the Cryo group muscles
showed a 42% decrease in strength production from pre-fatigue to
post-fatigue tetanic stimulus (p,0.05, Figure 7A). Although
strength production at pre-fatigue tetanic stimulus was also lower
in the Cryo+Leu group muscles than in the control group muscles
(58% lower; p,0.05, Figure 7A), the decrease in strength
production from pre-fatigue to post-fatigue tetanic stimulus seen
in the Cryo group muscles was not observed in the Cryo+Leu
group muscles (Figure 7A).
At four time points during the fatigue protocol (1st, 4th, 7th, and
10th contractions), the strength of the soleus muscle was measured.
The control muscle significantly decreased muscle strength
Figure 2. Leucine supplementation reduces area density of collagen type III in regenerating muscles. A: Soleus muscle cross sections
immunostained for collagen type III. C: intact control muscle; Leu: control muscles supplemented only with leucine from the time point of post-
cryolesion day 10; Cryo: damaged muscle analysed on post-cryolesion day 10; and, Cryo+Leu: leucine-supplemented damaged muscle analysed on
post-cryolesion day 10. Bar = 50 mm. B: Area density of collagen type III (percentage of the whole muscle cross section) in soleus muscles. Data are
presented as mean6SD (n = 5). a p,0.05 vs. C and Leu; b p,0.05 vs. Cryo.
doi:10.1371/journal.pone.0085283.g002
Figure 3. Leucine supplementation reduces incidence of
macrophages. Number of macrophages per cubic millimeter of
soleus muscles. C: intact control muscles; Leu: control muscles
supplemented only with leucine from the time point of post-cryolesion
day 3; Cryo: damaged muscles analysed on post-cryolesion day 3; and,
Cryo+Leu: leucine-supplemented damaged muscles analysed on post-
cryolesion day 3. Data are presented as mean6SD (n = 5). a p,0.05 vs. C
and Leu; b p,0.05 vs. Cryo.
doi:10.1371/journal.pone.0085283.g003
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beginning at the 4th contraction stimulus of the fatigue protocol (a
26% decrease vs. the 1st contraction), and persisting at the 7th and
10th contractions (31% and 27%, respectively; p,0.05, Figure 7B).
However, in the Leu group, soleus muscle strength did not vary at
the 1st, 4th, 7th, and 10th contractions of fatigue protocol
(Figure 7B). Muscle strength at the 1st, 4th, 7th, and 10th
contractions were significantly (56%, 46%, 57%, and 63%) lower
in the Cryo group than in the respective contractions in control
group (p,0.05, Figure 7B). In the Cryo group, muscle strength
was also significantly (,37%) lower at the 7th and 10th
contractions in comparison with the 1st contraction (p,0.05,
Figure 7B). In addition, muscle strength at the 1st, 4th, 7th, and 10th
contractions were lower in the Cryo+Leu group (62%, 52%, 50%,
and 57%) than in the respective contractions in control group (p,
0.05, Figure 7B). However, as in our analysis of strength
production, the Cryo+Leu group did not present a decrease in
muscle strength at the 4th, 7th and 10th contractions, in comparison
with that observed at the 1st contraction (Figure 7B).
Discussion
Skeletal muscle regeneration is an essential process that
contributes to the maintenance of muscle mass and function
throughout life. Given that muscle mass regulation is key to the
success of the muscle regeneration process, supplementation with
leucine, an ergogenic agent, represents a good strategy for
maximizing muscle mass recovery after various events related to
muscle disorders. In the present study, we have shown that leucine
supplementation, started 3 days prior to cryolesion, does not
protect the muscle against injury, however can benefit the
structure and function of regenerating muscle through attenuation
of protein ubiquitination.
Initially, we observed that although leucine supplementation
increased myofiber size in uninjured soleus muscle, it did not alter
muscle weight when compared to control. Previous studies
corroborate our data, because long-term leucine supplementation
(10 days to 8 weeks of administration, at the same dose utilized in
the present study) does not affect the weight of the gastrocnemius
or soleus muscles [38,39,40]. This effect might be related to a
leucine-mediated decrease in the expression of proteins that
constitute the extracellular matrix.
A recent study has shown that the internal region of the
proteoglycan decorin, which is rich in leucine, interacts with low-
density lipoprotein receptor-related protein-1, modulating trans-
forming growth factor beta (TGF-b)-dependent signalling, and
consequently inhibiting the TGF-b-dependent fibrotic response in
skeletal muscles [41]. In order to address this issue, we evaluated
the expression of collagen type III, an extracellular matrix protein
present mainly on endomysium and perimysium of skeletal muscle
tissue [42,43]. Although leucine was unable to attenuate the
expression of collagen type III in uninjured muscles, other proteins
from extracellular matrix might be more responsive to leucine.
Accordingly, uninjured muscles subjected to the longest leucine
treatment (Day 10, Table 1) increased their weight compared to
those that received the shortest one (Day 1, Table 1); therefore
even though uninjured muscles are less responsive to leucine, the
leucine effects seem to reflect on muscle weight over the course of
approximately 10 days. On the other hand, under the regenerative
process, leucine significantly reduced the intramuscular expression
of collagen type III, which may contribute to a more effective
repair of the satellite cell niche and its vascular and neural
networks.
In line with the beneficial effect of leucine on reconstitution of
extracellular matrix component, leucine was able to robustly
reduce macrophage infiltration at 3 days post-cryolesion. Accord-
Figure 4. Leucine supplementation does not activate PI3K/Akt/mTOR signalling pathway in regenerating muscles. A: Representative
Western blots of elements from the PI3K/Akt/mTOR signalling pathway. Muscle groups are identified at the top. C, intact control muscle; Leu, control
muscles supplemented only with leucine from the time point of post-cryolesion day 10; Cryo, damaged muscle analysed on post-cryolesion day 10;
and Cryo+Leu, leucine-supplemented damaged muscle analysed on post-cryolesion day 10. B: Densitometry analyses of elements from the PI3K/Akt/
mTOR signalling pathway. Blots were reacted with antibodies specific for mTOR; phosphorylated mTOR at Ser2448 residue; phosphorylated p70 at
Ser371 and Thr389 residues; 4E-BP1; p-4E-BP1 at Thr70 and Thr37/46 residues; eIF4E; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which
was used as standard. Mw: molecular weight. Data are presented as mean6SD (n = 4). a p,0.05 vs. C and Leu; b p,0.05 vs. Cryo.
doi:10.1371/journal.pone.0085283.g004
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ing to Nicastro et al. [44], branched-chain amino acids, which
include leucine, may influence the inflammatory status of a tissue
through transamination of glutamate in order to increase synthesis
of glutamine, an amino acid highly consumed by inflammatory
cells under pathological conditions. Furthermore, leucine functions
as a nitrogen donor for the production of glutamine in skeletal
muscle [45]; therefore the regenerating muscles supplemented
with leucine might have an acceleration of inflammatory process
installation and a more efficient function of immune cells
stimulated by increased amino acid substrates. Future studies
should deepen the investigation regarding molecular mechanisms
mediated by leucine in inflammatory process.
We also found that leucine supplementation resulted in an
increase in the size of regenerating myofibers on post-cryolesion
day 10. We investigated this effect, in order to determine whether
it was related to the activation of elements involved in the PI3K/
Akt/mTOR protein synthesis pathway. As expected, we found
that, at 10 days after cryolesion, there was activation of mTOR
and p70S6K in regenerating muscles. As demonstrated by [6,30],
post-cryolesion day 10 is a time point characterized by intense
protein synthesis, together with activation of mTOR and p70S6K,
in order to recover muscle mass. However, we observed no 10-day
post-cryolesion changes in 4E-BP1 phosphorylation or eIF4E,
suggesting that the protein synthesis does not involve the activation
of translation initiation factors at this time point in the muscle
regeneration process.
In uninjured muscles, leucine supplementation did not induce
activation of any of the PI3K/Akt/mTOR pathway elements
evaluated. Various studies have shown that a single bolus of
leucine is able to stimulate the PI3K/Akt/mTOR pathway
[27,31,32,46]. However, studies of long-term leucine supplemen-
tation (5–8 weeks of treatment) have demonstrated that the
activation of this pathway in the soleus muscle is not sustained over
time [38,39], a finding in agreement with those of the present
study. In fact, Suryawan et al. showed that leucine-induced
stimulation of muscle protein synthesis is not maintained for
prolonged periods; because there is a decay in the circulating
essential amino acids, which are utilised for protein synthesis [47].
Those authors found that although the activation of translation
initiation factors was preserved at 2-h after an infusion of leucine,
the stimulation of muscle protein synthesis was not, because of the
leucine-induced reduction in the concentrations of essential amino
acids [47]. In the present study, we show for the first time that
leucine supplementation slightly decreased p-mTOR (at Ser2448)
Figure 5. Leucine supplementation reduces FOXO3a activation in regenerating muscles. A: Soleus muscle cross sections immunostained
for FOXO3a. Activation of FOXO3a was assessed by quantifying FOXO3a positive nuclei per cubic millimeter. Post-cryolesion times are identified at
the top. C: intact control muscle; Leu: control muscles supplemented only with leucine from the time points of post-cryolesion day 3 and 10,
respectively; Cryo: damaged muscle analysed on post-cryolesion days 3 or 10, respectively; and, Cryo+Leu: leucine-supplemented damaged muscle
analysed on post-cryolesion days 3 or 10, respectively. Arrowheads indicate FOXO3a, DAPI (nucleus staining), and merge of FOXO3a and DAPI.
Bar = 50 mm. B: Number of FOXO3a positive nuclei per cubic millimeter of soleus muscles from post-cryolesion day 3 (panel a) and 10 days (panel b).
Data are presented as mean6SD (n = 5). a p,0.05 vs. C; b p,0.05 vs. Cryo group.
doi:10.1371/journal.pone.0085283.g005
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expression, and had no effect on other elements of PI3K/Akt/
mTOR pathway in regenerating muscles at post-cryolesion day
10. Accordingly, Baptista et al. [28] observed that leucine
supplementation did not alter protein synthesis in soleus muscles
after 7 days of immobilization. These results lead us to the
interpretation that the role of leucine in the recovery of
regenerating muscle mass is independent of protein synthesis
modulation and dependent on muscle proteolysis activation.
In order to test the hypothesis that leucine reduces protein
degradation, thus favouring muscle mass gain, we determined
FOXO3a activation and the amount of ubiquitinated proteins. As
previously demonstrated, protein ubiquitination increases at 1–14
days after muscle damage [6], which is in agreement with our
results showing that regenerating muscles had increased FOXO3a
activation, which may lead to transcription activation of E3 ligases
[18,19], and subsequent elevated amount of ubiquitinated proteins
on post-cryolesion days 3 and 10.
We found that leucine supplementation diminished FOXO3a
activation and the amount of ubiquitinated proteins in the soleus
muscle at post-cryolesion days 3 and 10, suggesting that muscle
proteolysis is attenuated by leucine. This finding is in agreement
with those of Baptista et al. [28], who showed that leucine
minimizes E3 ligase gene expression and attenuates overall protein
ubiquitination in soleus muscles after 7 days of immobilization. In
addition, a single leucine infusion has been shown to decrease
chymotrypsin and trypsin-like activities, as well as proteasome-
dependent proteolysis, in the skeletal muscles of 8-month-old rats
[40].
In order to determine whether the morphological alteration
induced by leucine had a functional impact, we analysed muscle
contraction at post-cryolesion day 10. As has previously been
demonstrated [6,30], we found that cryolesion provoked a
decrease in tetanic contraction. In the present study, leucine
supplementation prevented fatigue in uninjured muscles, which
may be due to a greater accumulation of glycogen and an increase
in the content of intracellular ATP after supplementation, as it has
been shown in gastrocnemius muscles treated with the leucine
metabolite beta-hydroxy-beta-methylbutyrate [48]. We also found
that leucine treatment prevented fatigue in injured muscles,
indicating that the gain in myofiber CSA through leucine-induced
attenuation of protein ubiquitination was relevant to muscle
function. Alternatively, the mechanism of the leucine-associated
increase in myofiber caliber during regeneration might involve an
increase in the proliferation of myogenic precursor cells, given that
Figure 6. Leucine supplementation reduces ubiquitinated protein accumulation. A: Representative Western blots of ubiquitinated
proteins. Samples were analysed at two different time points of experimental protocol (3 and 10 days post-cryolesion). Muscle groups and
experimental time points are identified at the top. C, intact control muscle; Leu, control muscles supplemented only with leucine from the time points
of post-cryolesion day 3 and 10, respectively; Cryo, damaged muscle analysed on post-cryolesion days 3 and 10, respectively; and Cryo+Leu, leucine-
supplemented damaged muscle analysed on post-cryolesion days 3 and 10, respectively. B: Densitometry analyses of ubiquitinated proteins at 3
(panel a) and 10 days (panel b) of experimental protocol. Blots were reacted with antibody specific for ubiquitin. Mw: molecular weight. Data are
presented as mean6SD (n = 4). a p,0.05 vs. C and Leu; b p,0.05 vs. Cryo.
doi:10.1371/journal.pone.0085283.g006
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leucine has been shown to increase the in vitro proliferation of
satellite cells isolated from pigs [49].
Although our previous experiments showed that saline-gavaged
rats did not have morphological changes compared to those from
intact animals (data not shown), future investigations should use a
more appropriate control group by supplementing animals with
equimolar doses of some other amino acid besides leucine. This
procedure would systematically help to confirm the beneficial
effects of leucine on skeletal muscle regeneration.
To our knowledge, this is the first study to demonstrate that
leucine supplementation improves the recovery of myofiber size
and muscle function of regenerating soleus muscle through
attenuation of protein ubiquitination. These findings are relevant
for clinical application in an effort to accelerate recovery of
function in conditions of muscle injury (e.g. sport injuries, muscle
damage caused by surgical intervention and frostbite) when
appropriate repair of muscle can significantly decrease rehabili-
tation time. Further studies are needed in order to investigate the
potential therapeutic effects of leucine in muscle disorders
involving muscle damage.
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